Lexicon Pharmaceuticals | LXRX - La Marge Brute Sur Les Ventes





La Marge Brute Sur Les Ventes Changement Date
Abbott USD 5.86B 675M 2026-03
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
AstraZeneca USD 12.61B 225M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Illumina USD 721M 38M 2026-03
Insmed USD 217.69M 106.25M 2025-12
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
J&J USD 17.24B 642M 2026-03
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
MannKind USD 78.31M 76.21M 2025-12
Merck USD 10.85B 2.57B 2025-12
Moderna USD -566M 792M 2026-03
Novartis USD 10.07B 184M 2026-03
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12